Mohit Bansal
Stock Analyst at Wells Fargo
(4.21)
# 477
Out of 5,015 analysts
172
Total ratings
64.36%
Success rate
10.5%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Overweight | $240 → $260 | $230.50 | +12.80% | 10 | Sep 12, 2025 | |
| TVTX Travere Therapeutics | Maintains: Overweight | $27 → $35 | $25.16 | +39.11% | 5 | Sep 11, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Overweight | $26 → $50 | $42.16 | +18.60% | 2 | Sep 11, 2025 | |
| MIST Milestone Pharmaceuticals | Initiates: Overweight | $4 | $1.99 | +101.01% | 1 | Sep 11, 2025 | |
| VRTX Vertex Pharmaceuticals | Upgrades: Overweight | $460 | $407.79 | +12.80% | 11 | Aug 6, 2025 | |
| BNTX BioNTech SE | Maintains: Overweight | $170 → $150 | $102.06 | +46.97% | 2 | Aug 5, 2025 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $97 → $90 | $85.99 | +4.66% | 11 | Jul 30, 2025 | |
| REGN Regeneron Pharmaceuticals | Downgrades: Equal-Weight | $700 → $580 | $564.63 | +2.72% | 18 | May 30, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $50 → $47 | $39.64 | +18.57% | 2 | May 13, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $60 → $65 | $64.10 | +1.40% | 7 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $62 → $53 | $43.96 | +20.56% | 9 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $7 → $1 | $1.59 | -36.91% | 4 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $970 → $1,100 | $833.49 | +31.98% | 17 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $140 | $117.18 | +19.47% | 11 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $165 → $140 | $146.57 | -4.48% | 14 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $130 → $170 | $135.43 | +25.53% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $335 → $280 | $290.13 | -3.49% | 10 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $21.35 | +40.52% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $30.09 | +132.64% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $90 | $52.32 | +72.02% | 5 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $24.78 | +21.07% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $136.63 | +24.42% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $15.27 | +12,178.98% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $1.84 | +1,856.52% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $13.40 | +41.79% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $5 | $0.18 | +2,604.16% | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.27 | +4,624.41% | 4 | Dec 3, 2019 |
AbbVie
Sep 12, 2025
Maintains: Overweight
Price Target: $240 → $260
Current: $230.50
Upside: +12.80%
Travere Therapeutics
Sep 11, 2025
Maintains: Overweight
Price Target: $27 → $35
Current: $25.16
Upside: +39.11%
Mineralys Therapeutics
Sep 11, 2025
Maintains: Overweight
Price Target: $26 → $50
Current: $42.16
Upside: +18.60%
Milestone Pharmaceuticals
Sep 11, 2025
Initiates: Overweight
Price Target: $4
Current: $1.99
Upside: +101.01%
Vertex Pharmaceuticals
Aug 6, 2025
Upgrades: Overweight
Price Target: $460
Current: $407.79
Upside: +12.80%
BioNTech SE
Aug 5, 2025
Maintains: Overweight
Price Target: $170 → $150
Current: $102.06
Upside: +46.97%
Merck & Co.
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $97 → $90
Current: $85.99
Upside: +4.66%
Regeneron Pharmaceuticals
May 30, 2025
Downgrades: Equal-Weight
Price Target: $700 → $580
Current: $564.63
Upside: +2.72%
Xenon Pharmaceuticals
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $39.64
Upside: +18.57%
Halozyme Therapeutics
May 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $65
Current: $64.10
Upside: +1.40%
Apr 28, 2025
Maintains: Equal-Weight
Price Target: $62 → $53
Current: $43.96
Upside: +20.56%
Apr 15, 2025
Downgrades: Equal-Weight
Price Target: $7 → $1
Current: $1.59
Upside: -36.91%
Mar 5, 2025
Maintains: Overweight
Price Target: $970 → $1,100
Current: $833.49
Upside: +31.98%
Mar 5, 2025
Maintains: Overweight
Price Target: $120 → $140
Current: $117.18
Upside: +19.47%
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $165 → $140
Current: $146.57
Upside: -4.48%
Feb 13, 2025
Upgrades: Overweight
Price Target: $130 → $170
Current: $135.43
Upside: +25.53%
Jan 10, 2025
Maintains: Equal-Weight
Price Target: $335 → $280
Current: $290.13
Upside: -3.49%
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $21.35
Upside: +40.52%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $30.09
Upside: +132.64%
Sep 17, 2024
Maintains: Overweight
Price Target: $115 → $90
Current: $52.32
Upside: +72.02%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $24.78
Upside: +21.07%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $136.63
Upside: +24.42%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $15.27
Upside: +12,178.98%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $1.84
Upside: +1,856.52%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $13.40
Upside: +41.79%
Apr 27, 2020
Maintains: Buy
Price Target: $8 → $5
Current: $0.18
Upside: +2,604.16%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.27
Upside: +4,624.41%